ST078925 analog-substitute to validated inhibitor #6, Figure 3. of the paper
3-(2-adamantanylethyl)-2-[(4-chlorophenyl)azamethylene]-4-oxo-1,3-thiazaperhyd roine-6-carboxylic acid ; 2H-1, 3-thiazine-6-carboxylicacid, 2-[(4-chlorophenyl) imino] tetrahydro-4-oxo-3-(2-tricyclo[188.8.131.52, 7] dec-1-ylethyl-)
Contact us to order Please list required amounts.
In addition, TimTec assembled small targeted compound collection of over 300 compounds-analogs based on three validated O-GlcNAc Transferase inhibitors (following the results of the discovery at Department of Microbiology and Molecular Genetics, HUMS)
Gross, B.J, Kraybill, B.C., Walker, S. Discovery of O-GlcNAc Transferase Inhibitors. Department of Microbiology and Molecular Genetics, Harvard Medical School. JACS Communications, published on Web 09/29/05; J. Am. Chem. Soc. 2005, 127, 14588-14589.
Discovery of O-GlcNAc Transferase Inhibitors Harvard Medical School
Filhoulaud, G., et al. The hexosamine biosynthesis pathway is essential for pancreatic beta cell development. J Biol Chem. 2009 Sep 4;284(36):24583-94.
Zafir A., Readnower R., et.al. Protein O-GlcNAcylation is a Novel Cytoprotective Signal in Cardiac Stem Cells. Stem Cells. 2012 April; 31(4): 765–775.
800-574-7391P: 302-292-8500F: 302-292-8520
TimTec in Russia
TimTec in China